NCT06302348View on ClinicalTrials.gov

A Study of Sepiapterin in Participants With Phenylketonuria (PKU)

PHASE3RecruitingINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

February 28, 2031

Study Completion Date

February 28, 2031

Conditions

Phenylketonuria

Interventions

DRUG

Sepiapterin

Sepiapterin powder for oral use will be suspended in water or apple juice prior to administration.

Trial Locations (1)

46202

RECRUITING

Indiana University, Indianapolis

Sponsors

Lead Sponsor

PTC Therapeutics

All Listed Sponsors

lead

PTC Therapeutics

INDUSTRY

NCT06302348 - A Study of Sepiapterin in Participants With Phenylketonuria (PKU) | Biotech Hunter | Biotech Hunter